Published in JAMA on November 22, 1965
Cooperative effect of the attenuation determinants derived from poliovirus sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J Virol (2007) 1.54
Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol (2003) 1.48
An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol (2007) 1.41
Establishment of a poliovirus oral infection system in human poliovirus receptor-expressing transgenic mice that are deficient in alpha/beta interferon receptor. J Virol (2007) 1.40
Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J Virol (2010) 1.40
A Sabin 3-derived poliovirus recombinant contained a sequence homologous with indigenous human enterovirus species C in the viral polymerase coding region. J Virol (2005) 1.23
Genetic determinants of cell type-specific poliovirus propagation in HEK 293 cells. J Virol (2005) 1.20
Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus. J Virol (1995) 1.12
Oxysterol-binding protein family I is the target of minor enviroxime-like compounds. J Virol (2013) 0.93
Valosin-containing protein (VCP/p97) is required for poliovirus replication and is involved in cellular protein secretion pathway in poliovirus infection. J Virol (2012) 0.91
Passive immunization against poliomyelitis: the Hammon gamma globulin field trials, 1951-1953. Am J Public Health (2005) 0.88
Lessons from the eradication of smallpox: an interview with D. A. Henderson. Philos Trans R Soc Lond B Biol Sci (2013) 0.85
Poliomyelitis in Japan during the period 1962-68 after the introduction of mass vaccination with Sabin vaccine. Bull World Health Organ (1973) 0.80
Evidence on the safety and efficacy of live poliomyelitis vaccines currently in use, with special reference to type 3 poliovirus. Bull World Health Organ (1969) 0.75
Comparative Medicine: An Inclusive Crossover Discipline . Yale J Biol Med (2017) 0.75
Dyes as Microchemical Indicators of a New Immunity Phenomenon Affecting a Protozoon Parasite (Toxoplasma). Science (1948) 19.46
IDENTIFICATION OF THE FILTRABLE, TRANSMISSIBLE NEUROLYTIC AGENT ISOLATED FROM TOXOPLASMA-INFECTED TISSUE AS A NEW PLEUROPNEUMONIA-LIKE MICROBE. Science (1938) 11.12
TOXOPLASMA AND OBLIGATE INTRACELLULAR PARASITISM. Science (1937) 6.75
ISOLATION OF A FILTRABLE, TRANSMISSIBLE AGENT WITH "NEUROLYTI" PROPERTIES FROM TOXOPLASMA-INFECTED TISSUES. Science (1938) 5.54
AN ACQUIRED RESISTANCE OF GROWING ANIMALS TO CERTAIN NEUROTROPIC VIRUSES IN THE ABSENCE OF HUMORAL ANTIBODIES OR PREVIOUS EXPOSURE TO INFECTION. J Exp Med (1936) 5.38
MICE AS CARRIERS OF PATHOGENIC PLEUROPNEUMONIA-LIKE MICROORGANISMS. Science (1939) 4.76
EXPERIMENTAL PROLIFERATIVE ARTHRITIS IN MICE PRODUCED BY FILTRABLE, PLEUROPNEUMONIA-LIKE MICROORGANISMS. Science (1939) 4.64
PRODUCTION OF IMMUNITY TO DENGUE WITH VIRUS MODIFIED BY PROPAGATION IN MICE. Science (1945) 4.05
THE THERAPEUTIC EFFECTIVENESS OF A PRACTICALLY NONTOXIC NEW COMPOUND (CALCIUM AUROTHIOMALATE) IN EXPERIMENTAL, PROLIFERATIVE, CHRONIC ARTHRITIS OF MICE. Science (1940) 3.63
INSECTS AND EPIDEMIOLOGY OF POLIOMYELITIS. Science (1942) 3.59
Visceral lesions in infectious polyneuritis: (Infectious neuronitis, acute polyneuritis with facial diplegia, guillain-barré syndrome, landry's paralysis). Am J Pathol (1941) 3.52
FLIES AS CARRIERS OF POLIOMYELITIS VIRUS IN URBAN EPIDEMICS. Science (1941) 3.48
Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis (1985) 2.64
Virus-specific, labile, nonvirion antigen in herpesvirus-infected cells. Proc Natl Acad Sci U S A (1970) 2.04
Paralytic poliomyelitis: Old dogmas and new perspectives. Rev Infect Dis (1981) 1.62
Amantadine hydrochloride. Analysis of data related to its proposed use for prevention of A2 influenza virus disease in human beings. JAMA (1967) 1.52
POLIOMYELITIS IN A LABORATORY WORKER EXPOSED TO THE VIRUS. Science (1941) 1.48
Mortality from pneumonia and risk conditions during influenza epidemics. High influenza morbidity during nonepidemic years. JAMA (1977) 1.40
NUTRITION AS A FACTOR IN THE DEVELOPMENT OF CONSTITUTIONAL BARRIERS TO INVOLVEMENT OF THE NERVOUS SYSTEM BY CERTAIN VIRUSES. Science (1940) 1.28
Behaviour of Chimpanzee-avirulent Poliomyelitis Viruses in Experimentally Infected Human Volunteers. Br Med J (1955) 1.23
Perspectives on rapid elimination and ultimate global eradication of paralytic poliomyelitis caused by polioviruses. Eur J Epidemiol (1991) 1.15
Amantadine and influenza: evaluation of conflicting reports. J Infect Dis (1978) 1.15
Herpes simplex and herpes genitalis viruses in etiology of some human cancers. Proc Natl Acad Sci U S A (1973) 1.14
Vaccination against poliomyelitis in economically underdeveloped countries. Bull World Health Organ (1980) 1.12
Perspectives on current use of some virus vaccines in the USA. Measles, rubella, poliomyelitis, and influenza in the USA: contrasts in control by vaccination. Pediatr Res (1979) 1.09
Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry. Proc Natl Acad Sci U S A (1992) 1.04
Reproductive capacity and viability at higher temperatures of various transformed hamster cell lines. J Natl Cancer Inst (1969) 0.99
Strategies for elimination of poliomyelitis in different parts of the world with use of oral poliovirus vaccine. Rev Infect Dis (1984) 0.98
Measles, killer of millions in developing countries: strategy for rapid elimination and continuing control. Eur J Epidemiol (1991) 0.95
Poliomyelitis vaccination. Evaluation and direction in continuing application. Am J Clin Pathol (1978) 0.94
Increase in preexisting cellular antigen-combining groups at different times after infection with different viruses. Proc Natl Acad Sci U S A (1970) 0.93
Immunization against measles by aerosol. Rev Infect Dis (1983) 0.92
The Presence of Poliomyelitis Virus in Human Cases and Carriers During the Winter. Yale J Biol Med (1944) 0.91
Nonvirion antigens produced by herpes simplex viruses 1 and 2. Proc Natl Acad Sci U S A (1973) 0.90
Vaccine-associated poliomyelitis cases. Bull World Health Organ (1969) 0.90
Nature and source of mycoplasma in various tissue cultures. Ann N Y Acad Sci (1967) 0.88
MULTIPLICATION AND SPREAD OF THE VIRUS OF ST. LOUIS ENCEPHALITIS IN MICE WITH SPECIAL EMPHASIS ON ITS FATE IN THE ALIMENTARY TRACT. J Exp Med (1947) 0.88
High effectiveness of aerosolized chick embryo fibroblast measles vaccine in seven-month-old and older infants. J Infect Dis (1985) 0.87
Strategy for rapid elimination and continuing control of poliomyelitis and other vaccine preventable diseases of children in developing countries. Br Med J (Clin Res Ed) (1986) 0.86
CONSTITUTIONAL BARRIERS TO INVOLVEMENT OF THE NERVOUS SYSTEM BY CERTAIN VIRUSES. Science (1940) 0.86
Different effects of chloramphenicol, dactinomycin, and streptovitacin A on synthesis of tumor and virion antigens in SV40 virus-infected cells. Proc Natl Acad Sci U S A (1966) 0.84
Inadequate serological surveys for immunity to poliomyelitis. Inadequate indicators of immune status of communities using oral poliovirus vaccine and inadequate guides to vaccination policy. Med J Aust (1983) 0.84
Varicella-zoster virus vaccine. JAMA (1977) 0.84
Overview and horizons in prevention of some human infectious diseases by vaccination. Am J Clin Pathol (1978) 0.83
Effectiveness of AIDS vaccines. Science (1991) 0.81
Genetic phenomena in experimental viral carcinogenesis. Search for such phenomena in cancers of children. Am J Dis Child (1966) 0.80
Residual paralytic poliomyelitis in a tropical region of Brazil, 1969-1977: prevalence surveys in different age groups as indicators of changing incidence. Am J Epidemiol (1983) 0.80
Collaboration for accelerating progress in medical research. Science (1967) 0.80
Clinical trials of inhaled aerosol of human diploid and chick embryo measles vaccine. Lancet (1982) 0.80
Suppression of malignancy in human cancer cells: issues and challenges. Proc Natl Acad Sci U S A (1981) 0.78
Vaccine control of poliomyelitis in the 1980s. Yale J Biol Med (1983) 0.78
My last will and testament on rapid elimination and ultimate global eradication of poliomyelitis and measles. Pediatrics (1992) 0.77
HIV vaccination dilemma. Nature (1993) 0.76
Are the herpes simplex-genitalis viruses a cause of certain human cancers? Adv Pathobiol (1976) 0.76
Immunization: Evaluation of some currently available and prospective vaccines. JAMA (1981) 0.76
Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. 1960. Bull World Health Organ (1999) 0.76
Editorial: Misery of recurrent herpes: what to do? N Engl J Med (1975) 0.76
A STUDY OF THE THERAPEUTIC MECHANISM OF ANTI-PNEUMOCOCCIC SERUM ON THE EXPERIMENTAL DERMAL PNEUMOCOCCUS INFECTION IN RABBITS : III. THE INFLUENCE OF NON-SPECIFIC FACTORS. J Exp Med (1933) 0.75
Viral hepatitis: problems of incidence and control in military personnel. Yale J Biol Med (1976) 0.75
Herpes simplex-genitalis virus nonvirion antigens and their implication in certain human cancers: unconfirmed. Proc Natl Acad Sci U S A (1974) 0.75
Viral Infections of the Human Nervous System: Classification and General Considerations. Postgrad Med J (1950) 0.75
Acceptance of the Howland award. Pediatr Res (1974) 0.75
Priorities in research. Science (1993) 0.75
Measles, rubella, poliomyelitis, and influenza in the USA: contrasts in control by vaccination. Monogr Paediatr (1979) 0.75
Medicine and public health in Baltimore during the early years of the Sinai Hospital of Baltimore. Md Med J (1991) 0.75
Present status of the search for a viral etiology of human cancer. Proc Rudolf Virchow Med Soc City N Y (1967) 0.75
Influenza. Dev Biol Stand (1976) 0.75
Eradication of smallpox and elimination of poliomyelitis: contrasts in strategy. Jpn J Med Sci Biol (1981) 0.75
Round table discussion on "Unifying concepts of leukemia and related neoplasms in man and animals leading to eventual control and prevention". Concluding remarks of the chairman. Bibl Haematol (1973) 0.75
Judaism and Medicine. Perspect Biol Med (1983) 0.75
Search for viral etiology of human leukemia and lymphomas: past efforts and future perspectives. Ann Ist Super Sanita (1967) 0.75
[Problems of influenza vaccination]. Fortschr Med (1981) 0.75
Control of infectious diseases. J Infect Dis (1970) 0.75
Reflections on the qualitative and quantitative aspects of neurovirulence of different polioviruses. Dev Biol Stand (1993) 0.75
LABORATORY: LABORATORY AIDS IN THE DIAGNOSIS AND SERUM THERAPY OF PNEUMOCOCCUS PNEUMONIA. Am J Public Health Nations Health (1933) 0.75
Control of infectious diseases. Antimicrob Agents Chemother (Bethesda) (1969) 0.75
[Vaccination against poliomyelitis in developing countries]. Salud Publica Mex (1980) 0.75
Recent studies othe possible role of viruses in human cancer. Ann Ist Super Sanita (1965) 0.75
Proceedings: Cancer research in Israel: work of academic institutions and National Cancer Registry. Natl Cancer Inst Monogr (1974) 0.75
Current challenges in medical practice and research. Md Med J (1992) 0.75
[Experimental suppression of the malignity of human cancer cells and absence of immunity against human cancer]. Minerva Med (1982) 0.75
Vaccination at the portal of entry of infectious agents. Dev Biol Stand (1976) 0.75
[Poliomyelitis: results of liver virus vaccination]. Bol Oficina Sanit Panam (1968) 0.75
Further Consideration of a Suggested Simple Laboratory Test for Poliomyelitis Virus. Science (1949) 0.75
Multiple sclerosis--a critique and prospective. Adv Neurol (1974) 0.75